Valuation dashboard for Recursion Pharmaceuticals, Inc. (RXRX) with P/E N/A, P/B 2.21, EV/EBITDA -4.2 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering.
Analysis Summary
Recursion Pharmaceuticals, Inc. reported revenue of $74.7M in the most recent fiscal year, growing at a 5-year CAGR of 85.4%.
Trailing-twelve-month margins: gross margin 10.7%, operating margin -7.3%, net margin -7.0%.
At $3.68 (closing price, November 3, 2026), RXRX has negative trailing earnings (P/E not meaningful) and an ROE of -47.85%. Market capitalisation stands at $2.2B.
Balance sheet quality for RXRX: debt-to-equity ratio of 0.08, current ratio of 5.01 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.21 |
| EV / EBITDA | -4.2 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| RXRX | Recursion Pharmaceuticals, Inc. | $2.2B | 2.21 | -47.8% | |
| DNLI | Denali Therapeutics Inc. | $3.1B | 3.96 | -34.0% | |
| RLAY | Relay Therapeutics, Inc. | $3.8B | 3.97 | -42.3% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $134.5B | 34.15 | 6.44 | 20.1% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $100.2B | 21.51 | 2.96 | 15.1% |
| MRNA | Moderna, Inc. | $91.2B | 13.38 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
Price
| Price | $3.68 (closing price, November 3, 2026) |
| Market Cap | $2.2B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -47.85% |
| Return on Invested Capital | -43.66% |
| Return on Assets | -38.93% |
| Gross Margin | 10.74% |
| Operating Margin | -725.44% |
| Net Margin | -697.13% |
Related companies: DNLI · RLAY · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of RXRX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks